Extended trial tests new inhaled therapy for serious lung-heart condition

NCT ID NCT05649748

Ongoing Disease control Sponsor: Insmed Incorporated Source: ClinicalTrials.gov ↗

Summary

This study follows patients with pulmonary arterial hypertension (PAH) who continue taking an experimental inhaled powder medication called treprostinil palmitil. The main goal is to check the long-term safety and side effects of this treatment. Researchers will also monitor whether patients maintain improvements in walking ability and heart health markers over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

ARG001

Córdoba, X5000FPQ, Argentina
ARG004

Córdoba, X5000DCE, Argentina
ARG006

Rosario, Santa Fe Province, S2013KDS, Argentina
ARG007

San Miguel de Tucumán, Tucumán Province, T4000AXL, Argentina
ARG009

Quilmes, Buenos Aires, B1878GEG, Argentina
AUT001

Vienna, 1090, Austria
AUT002

Linz, Upper Austria, 4020, Austria
BEL003

Brussels, 1070, Belgium
BRA002

Blumenau, Santa Catarina, 89030-101, Brazil
BRA004

Belo Horizonte, Minas Gerais, 30430-142, Brazil
BRA006

Porto Alegre, Rio Grande do Sul, 90035-003, Brazil
DNK001

Aarhus, Central Jutland, 8200, Denmark
ESP001

Santander, 39008, Spain
ESP003

Seville, 41009, Spain
GBR001

Bath, Avon, BA1 3NG, United Kingdom
GER002

Lübeck, Schleswig-Holstein, 23562, Germany
GER003

München, Bavaria, 80639, Germany
GER005

Heidelberg, Baden-Wurttemberg, 69126, Germany
ITA001

Palermo, 90127, Italy
ITA002

Pavia, Lombardy, 27100, Italy
ITA004

Roma, 00161, Italy
ITA005

Monza, 20900, Italy
JPN002

Okayama, Okayama-ken, 701-1192, Japan
JPN003

Suita-Shi, Osaka, 564-8565, Japan
JPN004

Sapporo, Hokkaido, 060-8648, Japan
JPN005

Sapporo, Hokkaido, 060-8543, Japan
JPN006

Tsukuba, Ibaraki, 305-9576, Japan
JPN007

Kurume-shi, Hukuoka, 830-0011, Japan
MEX001

Monterrey, Nuevo León, 64718, Mexico
MEX003

Mexico City, 14080, Mexico
MEX004

San Luis Potosí City, 78250, Mexico
MEX005

Lomas de Guevara, Jalisco, 44657, Mexico
MYS002

Kuantan, Pahang, 25200, Malaysia
MYS004

Sungai Buloh, Selangor, 47000, Malaysia
MYS005

Alor Star, Kedah, 5460, Malaysia
PHL001

Quezon City, National Capital Region, 1100, Philippines
PHL002

Makati City, 1229, Philippines
SRB001

Belgrade, 11000, Serbia
SRB003

Belgrade, 11000, Serbia
USA001

Chicago, Illinois, 60612, United States
USA005

Jacksonville, Florida, 32224, United States
USA006

Chicago, Illinois, 60611, United States
USA011

Tampa, Florida, 33606, United States
USA016

Dallas, Texas, 75246, United States
USA102

New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.

PULMONARY ARTERIAL HYPERTENSION